iMMagine-3: A Phase 3, Randomized Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel (Anito-Cel) With Standard of Care in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) | Publicación